A multicenter real-world study covering global sites shows that CAR-T cell therapy for relapsed/refractory lymphoma achieves a complete remission (CR) rate of 58%, with median overall survival extended to 24.3 months. This therapy involves genetically modifying a patient's T cells to precisely attack tumors, but the incidence of cytokine release syndrome (CRS) and neurotoxicity is 62% and 34%, respectively, with grade 3 or higher severe events accounting for 12%.
In terms of costs, the total expenditure for standard international therapy (drugs + hospitalization + monitoring) ranges from $300,000 to $500,000, while top domestic centers (such as Shanghai Ruijin Hospital) can control overall costs within RMB 250,000-400,000, which is only 1/8 to 1/5 of the international cost.
Background and Significance
Since the approval of the first CAR-T product in 2017, over 20,000 lymphoma patients worldwide have received this treatment. This real-world data aggregates 1,276 patients from the United States, Europe, and Asia, with a median follow-up of 18 months. Results show that 74% of CR patients maintain remission after 12 months, significantly outperforming traditional salvage chemotherapy (historical CR rate of approximately 15%). Particularly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) subtypes, efficacy is stable. However, the study also warns that in elderly patients (>70 years) and those with high tumor burden, treatment-related mortality rises to 4.7%, necessitating strict patient selection.
Implications for International Patients
For domestic patients, this data provides two key decision-making bases: first, efficacy expectations—if meeting guideline criteria (at least prior second-line therapy), CAR-T can offer long-term survival opportunities; second, risk management—treatment must be conducted in centers with ICU and neurology support. Domestic institutions such as Peking University Cancer Hospital and the First Affiliated Hospital of Soochow University have established standardized protocols with CRS management experience aligned with international standards. Additionally, after national medical insurance negotiations, some CAR-T products have entered local commercial insurance schemes, reducing out-of-pocket costs by over 30%, while international patients seeking treatment in China can also save on additional cross-border insurance expenses.
How MedBridge Can Help
MedBridge (MedBridge Shanghai) specializes in cross-border healthcare, connecting you with authoritative CAR-T treatment institutions in China (such as List of Partner Hospitals in Shanghai), providing the following support:
- Based on real-world data, matching your or your family member's pathological subtype and prior treatment history to select the most suitable clinical trials or approved products (e.g., Yescarta, Breyanzi);
- Assisting in scheduling expert consultations to obtain individualized risk assessments (including predictive models for CRS and neurotoxicity probability);
- Providing cost estimates and insurance reimbursement plans for transparent total expenses;
- Coordinating full translation, visa, accommodation, and follow-up to ensure treatment continuity and safety.
If you or a family member are facing lymphoma treatment choices, contact us for one-on-one consultation. We will help you weigh benefits and risks based on the latest research data.
Related reading: List of Partner Hospitals in Shanghai